There are currently 1254 clinical trials in Columbus, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Nationwide Children's Hospital, Ohio State University Comprehensive Cancer Center, Ohio State University and The Ohio State University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Brief Cognitive Behavioral Therapy for People with Physical Disabilities
NCT05695430
Recruiting
The purpose of this study is to examine the effectiveness of a psychotherapy (non-medication) treatment, Brief Cognitive Behavioral Therapy for Suicide Prevention, in reducing suicide ideation and attempts for people with physical disabilities.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: The Ohio State Universitty Wexner Medical Center, Columbus, Ohio
Conditions: Suicide, Suicide, Attempted, Suicidal Ideation, Disability Physical, Disability Hearing, Disability, Vision
Register for Updates
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT03802695
Recruiting
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/14/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
Register for Updates
Study of DF1001 in Patients with Advanced Solid Tumors
NCT04143711
Recruiting
DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eli... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Solid Tumor, Adult
Register for Updates
A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer
NCT05226507
Recruiting
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
Register for Updates
Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease
NCT06482437
Recruiting
This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/14/2025
Locations: OSU Department of Neurology Division of Neuromuscular Diseases, Columbus, Ohio
Conditions: Charcot-Marie-Tooth Disease
Register for Updates
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
NCT04919369
Recruiting
This phase Ib trial is to find out the best dose and side effects of all-trans retinoic acid (ATRA) and atezolizumab in treating patients with non-small cell lung cancer that has come back (recurrent) or has spread to other places in the body (metastatic). All-trans retinoic acid (ATRA) is made in the body from vitamin A and helps cells to grow and develop. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Vertebroplasty with Radiation Therapy for Spine Metastatic Cancer Patients with Indeterminate Lesion (SINS Criteria)
NCT05178472
Recruiting
This clinical trial studies the side effects of stereotactic radiosurgery and how well it works with or without vertebroplasty, separation surgery, or immunotherapy in patients with cancer that is radiation resistant and has spread to the spine (spinal metastases). Spinal metastases are rapidly progressive, have poor prognosis, are extremely difficult to treat, and can effect patient quality of life and overall health. Immunotherapy is a type of standard of care therapy to boost or restore the a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Spine
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio +7 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156
Recruiting
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Ohio Health, Columbus, Ohio
Conditions: Myelofibrosis
Register for Updates
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
NCT05794139
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/12/2025
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Spinal Muscular Atrophy
Register for Updates
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
NCT04636814
Recruiting
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/11/2025
Locations: Chiesi Clinical Trial - Site 840713, Columbus, Ohio
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
NCT04830137
Recruiting
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: OSU Wexner Medical Center, Columbus, Ohio
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)
Register for Updates